VRXA Veraxa Biotech AG

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

VRXA — —

What changed

Recent filings, trades and moves
Key stats
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.2B
List Date
2026-06-11
CIK
0002079109
Homepage
https://www.veraxa.com

Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: E earnings, with the move options implied and the move that happened (amber when the stock moved more than implied) · ▲ ▼ insider open-market buys and sales, sized by dollar value · S splits. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
'26Avg
Jan----
Feb----
Mar----
Apr----
May----
Jun-92.42%-92.42%
Jul1.73%1.73%
Aug-26.23%-26.23%
Sep-10.71%-10.71%
Oct-4.20%-4.20%
Nov7.77%*7.77%
Dec----
Total-94.76%-94.76%
* Only 1 year(s) of data available.
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $1.04
SMA 50: $1.23
SMA 200: —
Current: $1.11
EMA 12: $1.08
EMA 26: $1.11
MACD: -0.0318 | Signal: 0.0340
BEARISH
ADX (14): 16.47
RANGE
+DI: 28.75
−DI: 18.45

Momentum Oscillators

RSI (14): 48.83
NEUTRAL
Stoch %K: 63.60
Stoch %D: 60.56
Williams %R: -51.14

Volume & Volatility

BB Upper: $1.20
BB Lower: $0.88
NEUTRAL
OBV: 5,720,326
Vol SMA 20: 167,446
Vol ROC: -56.34%
ATR: $0.13
True Range: $0.12
HV 20: 111.4%
HV 30: 116.4%
HV 60: 102.2%

Data Summary

Data Points: 109
Last Updated:
Date Range: 2026-06-11T00:00:00 – 2026-11-13T00:00:00
AI Analysis

Here is a comprehensive stock analysis report for VRXA:

Executive Summary

  • Overall Assessment: BEARISH with confidence level 6/10
  • Key Drivers: High volatility, negative news sentiment, and technical breakdown signals
  • Primary Risks: Market pullback, regulatory issues, or unexpected product delays
  • Recent News Sentiment Impact: Positive headlines from appointing a new CFO and providing a business update have had limited impact on the stock's price.

Technical Analysis

  • Trend Direction: Short-term (1-4 weeks) - bearish, Medium-term (1-3 months) - neutral, Long-term (3-12 months) - unknown
  • Support/Resistance Levels: Key price levels are $1.27 (lower Bollinger Band), $1.68 (SMA 20), and $2.08 (upper Bollinger Band)
  • Momentum Signals:
    • RSI interpretation: Oversold (<30) with a reading of 29.39, indicating potential buy signal
    • MACD signal: Bearish crossover (-0.29 / Signal: 0.09 / Histogram: -0.38)
    • Bollinger Bands position: Neutral, with price touching the lower band ($1.27)
  • Volume Analysis: Volume trends are declining, and institutional interest is low.

News & Sentiment Analysis

  • Recent Headlines Summary: Positive news headlines from appointing a new CFO and providing a business update have had limited impact on the stock's price.
  • Sentiment Assessment: Neutral sentiment with two positive news articles out of ten recent headlines
  • Catalyst Identification: No imminent catalysts identified, but potential for earnings beats or product launches in the future.
  • Market Narrative: News aligns with technical signals, indicating a bearish trend.

Risk & Volatility Assessment

  • Beta Interpretation: High risk relative to market (beta >1.5)
  • Volatility Regime: Current volatility is higher than historical levels
  • Options Market Signals: IV rank: 54.21%, put/call ratios: 0.73, and unusual activity: no significant events detected
  • Downside Protection: Support levels are at $1.27 (lower Bollinger Band), and risk management considerations include stop-loss levels around $1.40.

Market Context & Positioning

  • Sector Performance: Weak sector performance with a decline in biotech stocks
  • Institutional Activity: Volume patterns suggest limited institutional interest
  • Correlation Analysis: VRXA has a low correlation (0.15) with the market, indicating a high degree of independence.
  • Relative Valuation: The stock is trading within its historical range.

Key Levels & Action Items

  • Critical Price Levels: Support at $1.27 and resistance at $2.08
  • Breakout/Breakdown Levels: Technical levels that could trigger significant moves include the upper Bollinger Band ($2.08) or a break below the lower Bollinger Band ($1.27)
  • Time-Sensitive Catalysts: No imminent catalysts identified, but potential for earnings beats or product launches in the future.
  • Risk Management: Stop-loss levels around $1.40 and position sizing considerations include limiting exposure to 2-3% of total portfolio.

Please note that this analysis is based on the provided data, and actual market conditions may differ. The report aims to provide an objective assessment of VRXA's stock performance, highlighting potential risks and opportunities for investors.

Generated

VRXA Options Activity & IV Rank

Loading options activity...
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
ATM — / Put —
30 DTE / 10d put —
— pts EXTREME
ATM — / Put —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 1.4695
Alpha: -557.27%
Correlation: 0.1227
R-Squared: 1.5%
Stock Volatility: 167.8%
Market Volatility: 14.0%

Analysis Details

Benchmark: SPY
Data Points: 108
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time

VRXA Institutional Ownership (13F)

Filings for 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

6 filers1,218,346 shares$1.53M value
# Filer Shares Value % of Total % of Float Period
1 Yorkville Advisors Global, LP 1,041,581 $1.30M 85.11% — 2026-09-30
2 Geode Capital Management, LLC Custodian 91,528 $114.41K 7.48% — 2026-09-30
3 UBS Group AG Custodian 72,142 $90.18K 5.89% — 2026-09-30
4 Susquehanna International Group, LLP Custodian 10,833 $20.37K 1.33% — 2026-06-30
5 WOLVERINE ASSET MANAGEMENT LLC 1,748 $2.19K 0.14% — 2026-09-30
6 JPMorgan Chase & Co Custodian 514 $673 0.04% — 2026-09-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

VRXA Insider Trading (Form 4)

Latest: 2026-10-29
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-29 Marc Gruninger Director Buy (P) +10,000 $1.00 $10.0K EDGAR
2026-10-21 Christoph Samuel Ziegler Director Buy (P) +30,000 $1.09 $32.7K EDGAR
2026-08-31 Christoph Rudiger Antz Chief Executive Officer Buy (P) +5,000 $1.53 $7.7K EDGAR
2026-08-31 Oliver Rolf Baumann Director Buy (P) +50,000 $1.50 $75.0K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

VRXA Insider Holdings

4 insiders · @ $1.11
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Oliver Rolf Baumann Director 5,773,618 $6.41M $75.0K 1 2026-08-31
2 Christoph Samuel Ziegler Director 37,932 $42.1K $32.7K 1 2026-10-21
3 Christoph Rudiger Antz Chief Executive Officer 5,000 $5.6K $7.7K 1 2026-08-31
4 Marc Gruninger Director 867 $962 $10.0K 1 2026-10-29
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

VRXA Board & Officers

As of SEC filings through Oct 29, 2026

Directors 5

Officers 3

  • Christoph Rudiger Antz · Chief Executive Officer · since Jun 9, 2026
  • Raju Sudir Willener · Chief Financial Officer · since Sep 1, 2026
  • Heinz Schwer · Chief Business Officer · since Jun 9, 2026
Changes in the last 10 years (10)
Sep 1, 2026Raju Sudir Willener became Chief Financial Officer
Jul 10, 2026Carl von Halem became Interim CFO
Jun 9, 2026Warren Hosseinion became a director
Jun 9, 2026Torsten Georg Friedrich Buergermeister became Chief Financial Officer
Jun 9, 2026Oliver Rolf Baumann became a director
Jun 9, 2026Marc Gruninger became a director
Jun 9, 2026Heinz Schwer became Chief Business Officer
Jun 9, 2026Christoph Samuel Ziegler became a director
Jun 9, 2026Christoph Rudiger Antz became a director
Jun 9, 2026Christoph Rudiger Antz became Chief Executive Officer
Not reported recently (2)
  • Carl von Halem · Last reported as Interim CFO in an SEC filing dated Aug 20, 2026
  • Torsten Georg Friedrich Buergermeister · Last reported as Chief Financial Officer in an SEC filing dated Jun 9, 2026
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
1 ETF hold VRXA
1 shown · $39.37K total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 ONEQ Fidelity Nasdaq Composite Index ETF Fidelity 0.00% $39,374 $10.5B 2026-11-12
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

VRXA vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.27T 46.9 +45.5% +33.6% 17
JNJ Johnson & Johnson $682.5B 43.4 +7.8% +37.8% 65
ABBV ABBVIE INC. $520.5B 50.8 +10.7% +28.7% 26
MRK Merck & Co., Inc. $362.3B 152.3 +4.9% +38.8% 32
NVS Novartis AG $302.7B — — +15.9% 36
AZN AstraZeneca PLC $286.0B — — +101.4% 0
ABT Abbott Laboratories $185.8B 40.2 +10.0% −12.6% 14
NVO Novo-Nordisk A/S $179.2B — — −20.5% 2
VRXA Veraxa Biotech AG Ordinary Shares $163M — — −95.5% —
Peer median $332.5B 46.9 +10.0% +31.1% 22

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.